BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 27173004)

  • 1. Inhibitors of enzymes catalyzing modifications to histone lysine residues: structure, function and activity.
    Lillico R; Stesco N; Khorshid Amhad T; Cortes C; Namaka MP; Lakowski TM
    Future Med Chem; 2016 May; 8(8):879-97. PubMed ID: 27173004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of homogeneous nonradioactive methyltransferase and demethylase assays targeting histone H3 lysine 4.
    Gauthier N; Caron M; Pedro L; Arcand M; Blouin J; Labonté A; Normand C; Paquet V; Rodenbrock A; Roy M; Rouleau N; Beaudet L; Padrós J; Rodriguez-Suarez R
    J Biomol Screen; 2012 Jan; 17(1):49-58. PubMed ID: 21940714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors.
    Spannhoff A; Hauser AT; Heinke R; Sippl W; Jung M
    ChemMedChem; 2009 Oct; 4(10):1568-82. PubMed ID: 19739196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The future therapeutic potential of histone demethylases: A critical analysis.
    Natoli G; Testa G; De Santa F
    Curr Opin Drug Discov Devel; 2009 Sep; 12(5):607-15. PubMed ID: 19736620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural insights into histone lysine demethylation.
    Hou H; Yu H
    Curr Opin Struct Biol; 2010 Dec; 20(6):739-48. PubMed ID: 20970991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The re-expression of the epigenetically silenced e-cadherin gene by a polyamine analogue lysine-specific demethylase-1 (LSD1) inhibitor in human acute myeloid leukemia cell lines.
    Murray-Stewart T; Woster PM; Casero RA
    Amino Acids; 2014 Mar; 46(3):585-94. PubMed ID: 23508577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impairment of prostate cancer cell growth by a selective and reversible lysine-specific demethylase 1 inhibitor.
    Willmann D; Lim S; Wetzel S; Metzger E; Jandausch A; Wilk W; Jung M; Forne I; Imhof A; Janzer A; Kirfel J; Waldmann H; Schüle R; Buettner R
    Int J Cancer; 2012 Dec; 131(11):2704-9. PubMed ID: 22447389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure and function of histone H3 lysine 9 methyltransferases and demethylases.
    Krishnan S; Horowitz S; Trievel RC
    Chembiochem; 2011 Jan; 12(2):254-63. PubMed ID: 21243713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posttranslational modifications of the histone 3 tail and their impact on the activity of histone lysine demethylases in vitro.
    Lohse B; Helgstrand C; Kristensen JB; Leurs U; Cloos PA; Kristensen JL; Clausen RP
    PLoS One; 2013; 8(7):e67653. PubMed ID: 23844048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone modification therapy of cancer.
    Biancotto C; Frigè G; Minucci S
    Adv Genet; 2010; 70():341-86. PubMed ID: 20920755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemical probes for histone-modifying enzymes.
    Cole PA
    Nat Chem Biol; 2008 Oct; 4(10):590-7. PubMed ID: 18800048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells.
    Huang Y; Vasilatos SN; Boric L; Shaw PG; Davidson NE
    Breast Cancer Res Treat; 2012 Feb; 131(3):777-89. PubMed ID: 21452019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone lysine methylation and demethylation pathways in cancer.
    Varier RA; Timmers HT
    Biochim Biophys Acta; 2011 Jan; 1815(1):75-89. PubMed ID: 20951770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of lysine-specific demethylase 1 by the acyclic diterpenoid geranylgeranoic acid and its derivatives.
    Sakane C; Okitsu T; Wada A; Sagami H; Shidoji Y
    Biochem Biophys Res Commun; 2014 Jan; 444(1):24-9. PubMed ID: 24406160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cadmium induces histone H3 lysine methylation by inhibiting histone demethylase activity.
    Xiao C; Liu Y; Xie C; Tu W; Xia Y; Costa M; Zhou X
    Toxicol Sci; 2015 May; 145(1):80-9. PubMed ID: 25673502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphorylation of histone H3T6 by PKCbeta(I) controls demethylation at histone H3K4.
    Metzger E; Imhof A; Patel D; Kahl P; Hoffmeyer K; Friedrichs N; Müller JM; Greschik H; Kirfel J; Ji S; Kunowska N; Beisenherz-Huss C; Günther T; Buettner R; Schüle R
    Nature; 2010 Apr; 464(7289):792-6. PubMed ID: 20228790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for compounds that modulate epigenetic regulation of the transcriptome: an overview.
    Eglen RM; Reisine T
    J Biomol Screen; 2011 Dec; 16(10):1137-52. PubMed ID: 22002420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting histone lysine demethylases by truncating the histone 3 tail to obtain selective substrate-based inhibitors.
    Lohse B; Nielsen AL; Kristensen JB; Helgstrand C; Cloos PA; Olsen L; Gajhede M; Clausen RP; Kristensen JL
    Angew Chem Int Ed Engl; 2011 Sep; 50(39):9100-3. PubMed ID: 21919140
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of histone demethylases in cancer therapy.
    Hoffmann I; Roatsch M; Schmitt ML; Carlino L; Pippel M; Sippl W; Jung M
    Mol Oncol; 2012 Dec; 6(6):683-703. PubMed ID: 22902149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of tissue factor pathway inhibitor-2 (TFPI-2) expression by lysine-specific demethylase 1 and 2 (LSD1 and LSD2).
    Mino K; Nishimura S; Ninomiya S; Tujii H; Matsumori Y; Tsuchida M; Hosoi M; Koseki K; Wada S; Hasegawa M; Sasaki R; Murakami-Yamaguchi Y; Narita H; Suzuki T; Miyata N; Mizukami T
    Biosci Biotechnol Biochem; 2014; 78(6):1010-7. PubMed ID: 25036127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.